Seeking Alpha
  • Friday, October 24, 2014

  • 4:07 PM
    • Sagent Pharmaceuticals (SGNT -0.9%) will report Q3 results on November 4 before the open. The conference call will begin at 8:00 am CT/9:00 am ET.
    • Consensus view is a loss of ($0.04) per share on revenues of $64M.
    | Comment!
  • 3:43 PM
    • RadNet (RDNT +0.6%) will report Q3 results on November 6 before the open. The conference call will begin at 7:30 am PT/10:30 am ET.
    • Consensus view is EPS of $0.06 on revenues of $178M.
    | 1 Comment
  • 1:53 PM
    • Premier (PINC +0.6%) will report fiscal Q1 results on November 10 after the close. The conference call will begin at 5:00 pm ET.
    • Consensus view is EPS of $0.32 on revenues of $228M.
    | Comment!
  • 1:51 PM
    • Allergan (AGN +1.2%) will report Q3 results on Monday, October 27 before the open. The conference call will begin at 6:00 am PT/9:00 am ET.
    • Consensus view is EPS of $1.68 on revenues of $1.78B.
    | Comment!
  • 1:25 PM
    • Sigma-Aldrich (SIAL -0.4%) Q3 results: Revenues: $690M (+3.9%); COGS: $342M (+3.6%); R&D Expense: $17M (+6.3%); SG&A Expense: $152M (+1.3%); Operating Income: $154M (-2.5%); Net Income: $108M (-9.2%); EPS: $0.90 (-8.2%); Quick Assets: $886M (+22.7%); CF Ops: $484M (-0.4%).
    • No financial guidance given.
    | Comment!
  • 1:03 PM
    • Oxford Immunotec Global (OXFD -0.7%) will report Q3 results on November 4 before the open. The conference call will begin at 8:00 am ET.
    • Consensus view is a loss of ($0.38) per share on revenues of $12.9M.
    | Comment!
  • 12:59 PM
    • IMS Health Holdings (IMS -6.4%) Q3 results: Revenues: $656M (+3.6%); Information: $382M (+0.3%); Technology Sevices: $274M (+8.7%); Operating Expenses: $311M (+6.1%); Net Income: $47M (+335.0%); EPS: $0.14 (+300.0%); Quick Assets: $354.0M (-51.2%); CF Ops: $191M.
    • 2014 Guidance: Revenue growth of 5.5 - 5.7% from 5 - 6%; Adjusted EBITDA growth: 9.0 - 9.8% from 7.5 - 9%; Adjusted Net Income growth: 20 - 21% from 15 - 20%.
    | Comment!
  • 12:08 PM
    • Fresenius Medical Care (FMS +1.6%) places $500M aggregate principal amount of 4.125% senior unsecured notes due 2020 and $400M aggregate principal amount of 4.75% senior unsecured notes due 2024.
    • Proceeds will be used to repay short-term debt, for acquisitions and general corporate purposes.
    | Comment!
  • 11:41 AM
    • Nano cap IsoRay (ISR +29.2%) is up on double average volume on no news. The stock made a similar move on October 7 but couldn't hold the gain. Shares reversed off the high of $2.12 all the way down to $1.22 on October 16.
    | 10 Comments
  • 11:24 AM
    • LifePoint Hospitals (LPNT -0.8%) Q3 results: Revenues: $1,166M (+29.6%); Operating Income: $46.1M (-12.4%); Net Income: $28.7M (-15.8%); EPS: $0.59 (-13.2%); Quick Assets: $263M (-58.8%); CF Ops: $131.3M (+25.9%).
    • Admissions: 56,599 (+16.3%); Equivalent Admissions: 144,994 (+23.8%); Revenue/Equivalent Admission: $8.041 (+4.7%).
    • 2014 Guidance: Net Revenue: $4.45B - 4.50B from $4.25B - 4.35B; Adjusted EBITDA: $630M - 640M from $605M - 620M; Diluted EPS: $3.26- 3.39 from $2.99 - 3.19.
    | Comment!
  • 11:00 AM
    • Idexx Laboratories (IDXX +9.1%) Q3 results: Revenues: $383.5M (+13.4%); COGS: $170.2M (+11.6%); R&D Expense: $24.8M (+14.8%); SG&A: $116.3M (+17.8%); Operating Income: $72.2M (+10.2%); Net Income: $52.2M (+14.2%); EPS: $1.03 (+19.8%); Quick Assets: $292.7M (+4.9%).
    • 2014 Guidance: Adjusted revenue: $1,505M - 1,510M; Adjusted EPS: $3.85 - 3.90 from $3.79 to 3.86; EPS: $3.42 - 3.54 from $3.54 - 3.63; Free Cash Flow: 100 - 110% of net income; Capital Expenditures: ~ $75M
    • 2015 Guidance: Revenue: $1,690M - 1,710M; EPS: $4.38 - 4.48.
    | Comment!
  • 10:42 AM
    • Cutera (CUTR) will report Q3 results on November 3 after the close. The conference call will begin at 2:00 pm PT/5:00 pm ET.
    • Consensus view is a loss of ($0.13) per share on revenues of $18M.
    | Comment!
  • 10:34 AM
    • Sucampo Pharmaceuticals (SCMP) will report Q3 results on November 6 before the open. The conference call will begin at 8:30 am ET.
    • Consensus view is EPS of $0.04 on revenues of $26M.
    | Comment!
  • 10:30 AM
    • Alder BioPharmaceuticals (ALDR +1.3%) will report Q3 results on November 3 after the close. The conference call will begin at 2:00 pm PT/5:00 pm ET.
    • Consensus view is EPS of $0.05 on revenues of $14.8M.
    | Comment!
  • 10:26 AM
    • The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopts a final opinion that Ariad Pharmaceuticals' (ARIA -0.4%) Iclusig (ponatinib) can continue to be used in accordance with its already approved indications for the treatment of certain leukemias and its benefit-risk profile continues to be positive for these indications.
    • The committee also recommended revised labeling to include additional warnings about the risk of vascular events.
    | 1 Comment
  • 10:17 AM
    • Magellan Health (MGLN +1.3%) Q3 results: Net Revenue: $923.2M (+5.7%); Managed Care: $703M (-8.7%); PBM & Dispensing: $220.2M (+112.8%); Cost of Care: $495.2M (-12.3%); COGS: $202.2M (+107.4%); Net Income: $25.8M (-45.3%); EPS: $1.00 (-41.2%); CF Ops: $194.2M (13.4%).
    • 2014 Guidance: Net income: $63M - $77M from $53M - 69M; Segment profit: $243M - $258M from $238M - 258M; CF Ops: $207M - $226M from $204M - 226M; diluted EPS: $2.30 - $2.81 from $1.90 - $2.47; fully adjusted net income: $88M - $102M from $74.5M - $92.5M; adjusted EPS: $3.21 - $3.72 from $2.67 - $3.32.
    | Comment!
  • 10:14 AM
    • The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopts a positive opinion supporting the label expansion of Xtandi (enzalutamide) to include the treatment of adult men with metastatic castrate-resistant prostate cancer (mCRPC) who are asymptomatic or mildly symptomatic after failure of androgen-deprivation therapy in whom chemotherapy is not yet clinically indicated.
    • CHMP's positive recommendation is based on the Phase 3 Prevail study where enzalutamide reduced the risk of death by 29% compared to placebo. Treated patients also experienced a 17-month delay in the time to initiation of chemotherapy versus placebo.
    • Xtandi's current indication is for the treatment of adult men with mCRPC whose disease has progressed on or after docetaxel therapy.
    • Enzalutamide was developed by Medivation (MDVN +2%) in collaboration with Astellas Pharma (OTCPK:ALPMF) (OTCPK:ALPMY).
    • A final decision by the European Commission typically takes about 60 days.
    | Comment!
  • 9:49 AM
    • ImmunoGen (IMGN -3.1%) FQ1 results: Revenues: $13.2M (-23.3%); R&D Expense: $28.0M (+27.3%); SG&A: $7.1M (+9.2%); Operating Loss: ($21.9M) (-93.8%); Net Loss: ($22.3M) (-99.1%); Loss Per Share: ($0.26) (-100.0%); Quick Assets: $121.8M (-14.3%).
    • Fiscal 2015 Guidance: Revenues: $100M - 105M; operating expenses: $160M - 165M; net loss: ($60M - 65M); cash burn: ($55M - 60M); capex: $7M - 9M; quick assets at fiscal year end: $75M - 85M. All items unchanged from Q2 guidance.
    | Comment!
  • 9:41 AM
    • Nano cap protective gear maker Lakeland Industries (LAKE -0.1%) raises $11.2M in a private placement of common stock at $10 per share. Proceeds will be used to pay off an existing loan and for working capital and general corporate purposes. Shares currently trade hands for $15.25.
    • Lakeland is a member of the Ebola Small Cap Index because of the potential upside demand for its HAZMAT suits. Before the Ebola news onslaught, shares traded for ~$6. Prices peaked at $29.55 on October 14.
    | 2 Comments
  • 9:31 AM
    • Recent IPO Vitae Pharmaceuticals (NASDAQ:VTAE) is up 33% premarket on higher-than-normal volume in response to its announcement of results from a Phase 1 trial of its BACE inhibitor, VTP-37948, in Alzheimer's patients. The drug candidate appeared safe and tolerable. Partner Boehringer Ingelheim expects to initiate more Phase 1 studies to clarify the pharmacokinetic profile and ascending dose characteristics.
    | Comment!
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector